Intravenous administration of darbepoetin to NICU patients

Journal of Perinatology

Volumn 26, Issue 5, 2006, Pages 296-300

  Warwood, T L ^a   Ohls, R K ^b   Lambert, D K ^a   Jones, C ^a   Scoffield, S H ^a   Gupta, N ^c   Veng Pedersen, P ^c   Christensen, R D ^a  

^a McKay Dee Hospital Center   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Absolute reticulocyte count; Darbepoetin; Erythropoietin; Immature reticulocyte fraction; Pharmacodynamics; Pharmacokinetics

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DELIVERY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; FEMALE; GESTATIONAL AGE; HEMOGLOBINOPATHY; HUMAN; INFANT; INJECTION SITE REACTION; MALE; NEWBORN; NEWBORN INTENSIVE CARE; PHARMACODYNAMICS; RETICULOCYTE COUNT; SINGLE DRUG DOSE;

BIRTH WEIGHT; ERYTHROPOIETIN; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; MALE; PREMATURE BIRTH; RETICULOCYTE COUNT;

EID: 33646089416     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211498     Document Type: Article

References (14)

1. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(Suppl): 3-10.
2. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-299.
3. Warwood TL, Ohls RK, Wiedmeier SE, Lambert DK, Jones C, Scoffield SH et al. Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol 2005; 25: 725-730.
4. Davis BH, Ornvold K, Bigelow NC. Flow cytometric reticulocyte maturity index: A useful laboratory parameter of erythropoietic activity in anemia. Cytometry 1995; 22: 35-39.
5. Pedersen PV. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 1977; 5: 513-531.
6. www.aransep.com/professional/ckd/simple_conversion/ epoetin_to_aranesp.jsp.
7. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395.
8. Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 1996; 40: 376-380.
9. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998; 52: 235-249.
10. Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 2002; 17: 933-937.
11. De Palo T, Giordano M, Poalumbo F, Bellantuono R, Messina G, Colella V et al. Clinical experience with darbepoetin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004; 19: 337-340.
12. Buhrer C, Obladen M, Maier R, Muller C. Urinary losses of recombinant erythropoietin in preterm infants. J Pediatr 2003; 142: 425-453.
13. Bierer R, Peceny MC, Harterberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006 (in press).
14. Ledbetter DJ, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 2000; 35: 178-181.